trending Market Intelligence /marketintelligence/en/news-insights/trending/9-ckgmgmuae0bu2cnqaxaa2 content esgSubNav
In This List

Loxo Oncology completes rolling submission of FDA application for cancer drug

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Loxo Oncology completes rolling submission of FDA application for cancer drug

Loxo Oncology Inc. completed the rolling submission of its new drug application to the U.S. Food and Drug Administration for its cancer medicine larotrectinib.

The company seeks approval for the drug to treat solid tumors with the neurotrophic tyrosine receptor kinase, or NTRK, gene fusion that locally progressed or already spread. NTRK gene fusions are genetic alterations that can cause tumor growth.

Loxo Oncology initiated the rolling submission in December 2017. A marketing authorization application is expected to be filed with the EU in 2018.

The Stamford, Conn.-based company is co-developing the drug with Bayer AG.